现代放疗技术时代的半身照射(HBI)治疗骨转移——一项系统综述
该系统性综述评估半身照射(HBI)治疗多发性疼痛性骨转移的疗效与毒性。疼痛缓解通常在HBI后2-3周快速出现,总体疼痛缓解率中位数为84%(75.6-89%),完全疼痛缓解中位数为36%;毒性通常限于G1/G2,G3罕见;超过50%的患者可减少镇痛药用量。作者认为HBI安全有效,应重新考虑更频繁使用。
要点
- HBI后疼痛缓解通常快速出现,约在2-3周内。
- 总体疼痛缓解率中位数为84%(75.6-89%),完全疼痛缓解中位数为36%。
- 毒性通常限于G1/G2,G3病例非常罕见。
核心结论
- HBI是安全有效的方法,应再次考虑更频繁地使用。
研究设计与样本
- 系统综述,旨在呈现关于HBI疗效与潜在毒性的更新信息。
主要发现
- 疼痛缓解通常在HBI后2-3周快速出现。
- 所有系列中总体疼痛缓解率均较高,中位数为84%(75.6-89%),完全疼痛缓解中位数为36%。
- 毒性通常限于G1/G2,G3病例非常罕见。
- 超过50%的患者在HBI后可减少镇痛药摄入。
- 采用现代放疗技术时,大多数患者生活质量得到改善。
临床怎么用
- HBI可用于治疗多发性疼痛性骨转移患者。
- 现代技术如容积旋转调强放疗(VMAT)和螺旋断层放疗可更安全地照射复杂靶区。
- 作者认为HBI安全有效,应再次考虑更频繁地使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bone metastases (BMs) are the most common cause of cancer-related pain and radiation therapy plays a key role in treating pain caused by it. The half-body irradiation (HBI) is a modality that can be used to treat patients with multiple painful BMs. In the modern era, concerns about toxicity and the availability of new agents requiring robust bone marrow function have limited the use of HBI in advanced cancer. Concerns about HBI toxicity stem from outdated techniques; modern methods like volumetric modulated arc therapy (VMAT) and helical tomotherapy now allow safer irradiation of complex target volumes. We conducted a systematic review to present updated information about HBI efficacy and potential toxicity. Pain relief usually occurs very quickly 2-3 weeks after HBI. The overall pain response rate was high in all the series, accounting for a median of 84 % (75.6-89 %), with a median of 36 % complete pain response. The toxicity is usually limited to G1/G2, with very rare G3 cases. More than 50 % of patients can reduce analgesic intake after HBI. Additionally, with modern radiotherapy techniques, quality of life is improved in most patients. HBI is a safe and effective method and should once again be reconsidered for more frequent use.
引用
- Bilski M, Konat-Bąska K, Mastroleo F, et al. Half body irradiation (HBI) for bone metastases in the modern radiotherapy technique era - A systematic review. Clin Transl Radiat Oncol. 2024. PMID: 39290455. doi:10.1016/j.ctro.2024.100845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。